BRPI0509655A - uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina - Google Patents

uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina

Info

Publication number
BRPI0509655A
BRPI0509655A BRPI0509655-3A BRPI0509655A BRPI0509655A BR PI0509655 A BRPI0509655 A BR PI0509655A BR PI0509655 A BRPI0509655 A BR PI0509655A BR PI0509655 A BRPI0509655 A BR PI0509655A
Authority
BR
Brazil
Prior art keywords
purine
diamine derivatives
treatment
diamine
new
Prior art date
Application number
BRPI0509655-3A
Other languages
English (en)
Inventor
Rolf Baenteli
Patrick Chene
Stephen Paul Collingwood
Pascal Furet
Peter Meier
Joseph Schoepfer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0509655A publication Critical patent/BRPI0509655A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE DERIVADOS DE 9H-PURINA-2,6-DIAMINA NO TRATAMENTO DE DOENçAS PROLIFERATIVAS E NOVOS DERIVADOS DE 9H-PURINA-2,6-DIAMINA. A presente invenção se refere à aplicação de compostos de 9H-purina-2,6-diamina e sais dos mesmos no tratamento de doenças proliferativas e para a fabricação de preparações farmacêuticas para o tratamento das doenças referidas, preparações farmacêuticas compreendendo compostos de 9H-purina-2,6-diamina, novos compostos de 9H-purina-2,6-diamina, e um processo para a preparação dos novos compostos de 9H-purina-2,6- diamina.
BRPI0509655-3A 2004-04-05 2005-04-04 uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina BRPI0509655A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0407723.6A GB0407723D0 (en) 2004-04-05 2004-04-05 Organic compounds
PCT/EP2005/003521 WO2005097135A2 (en) 2004-04-05 2005-04-04 Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives

Publications (1)

Publication Number Publication Date
BRPI0509655A true BRPI0509655A (pt) 2007-10-09

Family

ID=32320386

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509655-3A BRPI0509655A (pt) 2004-04-05 2005-04-04 uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina

Country Status (12)

Country Link
US (1) US20070249639A1 (pt)
EP (1) EP1734968A2 (pt)
JP (1) JP2007531721A (pt)
KR (1) KR20070033962A (pt)
CN (1) CN1946405B (pt)
AU (1) AU2005230388B2 (pt)
BR (1) BRPI0509655A (pt)
CA (1) CA2559014A1 (pt)
GB (1) GB0407723D0 (pt)
MX (1) MXPA06011486A (pt)
RU (1) RU2006139005A (pt)
WO (1) WO2005097135A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
CN100526315C (zh) * 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EA017405B9 (ru) * 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
NZ577197A (en) 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
WO2008090181A1 (en) * 2007-01-23 2008-07-31 Palau Pharma, S. A. Purine derivatives
US8404674B2 (en) 2007-03-07 2013-03-26 Boehringer Ingelheim International Gmbh Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
KR101564233B1 (ko) * 2007-03-28 2015-10-29 뉴로서치 에이/에스 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도
EP2144911A2 (en) 2007-03-28 2010-01-20 NeuroSearch AS Purinyl derivatives and their use as potassium channel modulators
CN101289449A (zh) * 2007-04-20 2008-10-22 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和应用
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
CZ302225B6 (cs) * 2007-07-04 2010-12-29 Univerzita Palackého v Olomouci Substituované 6-anilinopurinové deriváty jako inhibitory cytokinin oxidasy a prípravky obsahující tyto slouceniny
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009238590A1 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
CN102260263A (zh) * 2010-05-26 2011-11-30 四川大学 一类二苯胺基嘌呤衍生物及制备方法和医药用途
EP2758402B9 (en) * 2011-09-22 2016-09-14 Pfizer Inc Pyrrolopyrimidine and purine derivatives
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
CN102746304B (zh) * 2012-06-21 2014-03-19 成都苑东药业有限公司 一种嘌呤胺类化合物及其制备方法
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
CN104418858B (zh) * 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CN107892691B (zh) * 2017-12-19 2020-04-28 西安交通大学 2,8,9-三取代-9h-嘌呤类化合物及其盐和应用
US20220251085A1 (en) * 2019-07-21 2022-08-11 University Of Virginia Patent Foundation Cysteine binding compositions and methods of use thereof
EP4146228A4 (en) * 2020-05-07 2024-10-30 Shanghai Huayu Biotechnology Co., Ltd. Combination cancer therapy using n2-quinoline or isoquinoline substituted purine derivatives
CN111925372A (zh) * 2020-08-11 2020-11-13 五邑大学 一种嘌呤核苷类化合物的修饰方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255485B1 (en) * 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases
HK1044334A1 (zh) * 1999-02-01 2002-10-18 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US6897307B2 (en) * 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
WO2004002990A2 (en) * 2002-06-27 2004-01-08 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
EP1556129A4 (en) * 2002-10-15 2011-02-09 Irm Llc COMPOSITIONS AND METHODS OF INDUCING OSTEOGENESIS
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation

Also Published As

Publication number Publication date
EP1734968A2 (en) 2006-12-27
WO2005097135A3 (en) 2006-02-16
WO2005097135A2 (en) 2005-10-20
CN1946405B (zh) 2010-10-13
MXPA06011486A (es) 2007-03-12
US20070249639A1 (en) 2007-10-25
CN1946405A (zh) 2007-04-11
GB0407723D0 (en) 2004-05-12
AU2005230388A1 (en) 2005-10-20
JP2007531721A (ja) 2007-11-08
RU2006139005A (ru) 2008-05-20
KR20070033962A (ko) 2007-03-27
CA2559014A1 (en) 2005-10-20
AU2005230388B2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
BRPI0509655A (pt) uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina
BRPI0513819A (pt) inibidores de hsp90
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
BRPI0416796A (pt) compostos orgánicos
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
BRPI0820622A2 (pt) Compostos derivados de aminotiazol, processo para a sua preparação, composição farmacêutica que os compreende, uso dos mesmos e métodos para o tratamento e/ou profilaxia de diabetes e outras enfermidades
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI0608297A2 (pt) composições de lipossomos
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
BRPI0720588B8 (pt) derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase
BRPI0515218A (pt) composto, composição farmacêutica, método para o tratamento de um mamìfero ou ser humano, método de uso do composto, novos intermediários, uso dos novos intermediários, processo para a preparação de um composto
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0512237A (pt) cis-imidazolinas
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0909082A2 (pt) imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
BRPI0915862A2 (pt) compostos derivados de tetraidrocinolina, processo para sua fabricação, composição farmacêutica que os compreende, uso dos mesmos e método para o tratamento ou profilaxia de diabetes e outras enfermidades
BRPI0510719A (pt) derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
BRPI0510778A (pt) composição farmacêutica, processo para a preparação da mesma, método para o tratamento de rinite, e, uso de uma composição

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.